Tune in to The Executive podcast every Friday for a compelling journey into the minds of industry titans, founders, and investors who have paved their way to success at the highest echelons of their fields. Explore thought-provoking interviews that provide actionable insights, strategic wisdom, and inspiring anecdotes, all aimed at empowering listeners to navigate their own paths to greatness.
Whether you're a young professional, emerging entrepreneur, seasoned executive, or ambitious investor, The Executive Podcast offers a diverse array of perspectives from leaders across tech, life sciences, aerospace, finance, and beyond, ensuring a wealth of valuable knowledge wherever you listen. Don't miss out on your weekly dose of motivation and education.
Subscribe and follow wherever you get your podcasts.
Embracing Ambiguity: Dr. Seth Lederman, CEO & Chairman of Tonix Pharmaceuticals
Dr. Seth Lederman, CEO and Chairman of Tonix Pharmaceuticals, shares insights into his journey from medical practice to pharmaceutical entrepreneurship. From his early days combating the AIDS epidemic to specializing in rheumatology and fibromyalgia research, Dr. Lederman discusses the lessons learned from founding and leading Tonix Pharmaceuticals.
Matthew Price, COO of Promontory Therapeutics
Matthew Price, COO of Promontory Therapeutics is an experienced biotech entrepreneur / C-level executive, and the only company co-founder named a 2022 Emerging Pharma Leader by Pharmaceutical Executive. He is responsible for industry collaborations with Pfizer and Merck KGaA, and for Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute.
Robert Jacks, President and CEO of Sparrow Therapeutics
Robert Jacks, has 20 years of experience in the biopharmaceutical industry. He has founded or co-founded multiple companies and raised more than $170 million with several successful exits.
Dr. Marcelo Bigal, President and CEO of Ventus Therapeutics
Dr. Marcelo Bigal, President and CEO of Ventus Therapeutics, a company that expects to become the leader in the field of using precision medicine to identify subsets of patients with severe chronic neurological conditions.
Vlad Vitoc, CEO of MAIA
Vlad Vitoc is the Founder & CEO of MAIA, an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Vlad and his team took MAIA public successfully in 2022 in one of the most difficult IPO markets in recent years.
Hans Keirstead, CEO of AIVITA
Hans Keirstead, is a serial entrepreneur and currently the Founder, CEO and Chairman of Aivita Biomedical, a biotechnology company developing personalized vaccines for the prevention of infectious disease and treatment of cancer. He has now founded four biotechnology companies with successful exits in his previous three companies. Dr. Keirstead also holds Board positions in several prominent biotechnology companies.
Mani Mohindru, CEO of Novasenta
Mani Mohindru, CEO of Novasenta has a non-traditional career path, starting as a scientist studying immune cells in the context of autoimmune diseases. She later worked in investment banking, which exposed her to different therapeutic areas, treatment modalities, and a full view of what a company can grow into. She then transitioned to the operations side of public biotechs as Chief Strategy Officer and eventually became a Chief Financial Officer before becoming the CEO of Novasena.
Brian Finrow, CEO of Lumen Bioscience
Brian Finrow is the CEO of Lumen Bioscience, where they are reinventing how biologic drugs are made. Unlike to a lot of Bioscience CEO’s, Brian comes from the legal industry having spent over 8 years at Cooley. Lumen's patented technology allows them to use the well-known food algae spirulina to deliver therapeutic proteins.
Joanne Mizell, COO of Banner|Aetna
Joanne Mizell is the Chief Operating Officer of Banner|Aetna. Banner Health and Aetna created a joint venture to improve the health care system for members, for providers, and for employers alike through new synergies, new partners, and simplification.